Stratification of Endometrial Carcinoma Patients Using Immunohistochemistry for Better Surgical Planning and Prognosis
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Endometrial Cancer
- Sponsor
- Zagazig University
- Enrollment
- 96
- Locations
- 1
- Primary Endpoint
- expression levels of p53/L1CAM/ER/PR
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The incidence of endometrial cancer (EC) is increasing .Different risk classifications are used to direct the primary and adjuvant therapy. The European Society for Medical Oncology - European Society of Gynaecological Oncology -European Society for Radiotherapy & Oncology (ESMO-ESGO- ESTRO) could guide the need for lymph node surgery pre-operatively, and also post-operatively to determine adjuvant treatment.
Low-risk patients are managed with surgery alone, while higher-risk group patients undergo more aggressive surgical options. So, it is important to identify new prognostic markers for better stratification of patients to avoid under- or over treatment of EC patients.
Investigators
Walid Mohamed Elnagar
Assistant professor of gynecology
Zagazig University
Eligibility Criteria
Inclusion Criteria
- •aged 36 -72 years;
- •Previously diagnosed with endometrial carcinoma;
- •Histological Type of the tumor;
- •Myometrial Invasion;
- •lymph Node Invasion;
- •Cervical Invasion;
- •Biomarkers expression.
Exclusion Criteria
- •Lack of tumor tissue in tissue block
Outcomes
Primary Outcomes
expression levels of p53/L1CAM/ER/PR
Time Frame: 36 Months
The Prognostic value of immunohistochemical detection of expression levels of p53/L1CAM/ER/PR in relation to ESMO-ESGO-ESTRO risk groups